Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ligand Pharm
(NQ:
LGND
)
104.50
+0.88 (+0.85%)
Streaming Delayed Price
Updated: 1:20 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharm
< Previous
1
2
3
4
5
6
Next >
Why Are Novan Shares Nosediving Today?
July 17, 2023
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to
Via
Benzinga
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
July 17, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
July 17, 2023
From
Novan, Inc.
Via
GlobeNewswire
Recap: Ligand Pharmaceuticals Q1 Earnings
May 04, 2023
Via
Benzinga
Ligand Pharmaceuticals Earnings Preview
February 21, 2023
Via
Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
December 23, 2022
Via
Benzinga
3 Stocks That Smart Investors Should Be Flocking to Now
May 30, 2023
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors.
Via
InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
May 16, 2023
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in
Via
Benzinga
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 16, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2023 Financial Results
May 04, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
April 24, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Earnings Scheduled For February 22, 2023
February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Via
Benzinga
Ligand to Report Fourth Quarter Financial Results on February 22
February 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
January 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
December 23, 2022
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...
Via
Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
December 16, 2022
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13.
Via
Benzinga
Ligand Pharma Issues Mixed Guidance For FY23
December 13, 2022
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its...
Via
Benzinga
Ligand Provides Highlights from its Investor and Analyst Day Event
December 13, 2022
From
Ligand Pharmaceuticals
Via
Business Wire
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
December 05, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Hold Investor and Analyst Day on December 13
November 16, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Earnings Outlook For Ligand Pharmaceuticals
November 04, 2022
Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 02, 2022
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Ligand Announces Completion of OmniAb Spin-Off
November 01, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Distribution of OmniAb Complete and Business Combination Closed
November 01, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.